A rare manifestation of Fabry’s disease

Zsanett Fricska Nagya, Krisztina Bencsika, Cecilia Rajda, Márta Morvay, Sándor Husz, Erika Vörös, Arndt Rolfes, Viktor Hont, Attila Dobozy, László Vécsei

Department of Neurology, Albert Szent-Gyögyi Medical and Pharmaceutical Centre, University of Szeged, Hungary

Department of Dermatology and Allergology, Albert Szent-Gyögyi Medical and Pharmaceutical Centre, University of Szeged, Hungary

Department of Radiology, Albert Szent-Gyögyi Medical and Pharmaceutical Centre, University of Szeged, Hungary

Department of Neurology, Neurobiological Laboratory, University Rostock, Germany

Fabry’s disease is a recessive X-linked genetic disease, caused by the deficiency of the α-galactosidase-A (GLA) enzyme [1]. Approximately 300 mutations are known to affect the 9 possible isoforms of the GLA gene.

Vascular endothelium, the heart, the brain and the kidneys are often involved [2]. Stroke, which is caused by alterations of cerebral vessels, is a frequent complication of the disease [3].

Case report: The patient (male, 42) was observed in 2001 due to hemiparesis. CT analysis led to the diagnosis of ischaemic stroke. Later the patient showed a progressive spastic quadraparesis. Laboratory test for thrombophilia was negative. MRI detected distended cerebral vessels and lesions of the white matter. The CSF test did not prove MS. The patient’s neurological state progressed with time. The patient developed psychoorganic syndrome. Histological examination of red papules led to the diagnosis of angio-keratoma corporis diffusum. Genetic examination detected a point mutation (C to T, Arg112Cys) in the GLA gene. The activity of the GLA enzyme was low. In order to trace renal and cardiac defects, the patient was regularly examined. To date these examinations revealed no alterations, and proteinuria did not appear. Symptoms of Fabry’s disease also appeared previously in the patient’s family.

Our case involving the Arg112Cys mutation is the second in which only the cerebrum and the skin are affected [4]. However, this mutation was already known from a classical Fabry’s disease case [5]. In this case the patient carried two mutations in the GLA gene, one of which was the Arg112Cys. Together, this mutation might affect an isoform of the enzyme which exerts its action mainly in the ectodermal tissues. This may be the cause of the limited organic manifestation.

Correspondence:
Professor László Vécsei
Department of Neurology
Albert Szent-Gyögyi Medical and Pharmaceutical Centre
University of Szeged
6 Semmelweis street
H-6701 Szeged, Hungary
E-Mail: vecsei@nepsy.szote.u-szeged.hu

References
The many reasons why you should choose SMW to publish your research

What Swiss Medical Weekly has to offer:

- SMW’s impact factor has been steadily rising. The 2005 impact factor is 1.226.
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

International Advisory Committee
Prof. K. E. Juhan Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haeufeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors:
http://www.smw.ch/set_authors.html

All manuscripts should be sent in electronic form, to:

EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch